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Objective: Fibroblast growth factor 21 (FGF21) has been shown to rapidly lower body weight in the Siberian hamster, a preclinical model of
adiposity. This induced negative energy balance mediated by FGF21 is associated with both lowered caloric intake and increased energy
expenditure. Previous research demonstrated that adipose tissue (AT) is one of the primary sites of FGF21 action and may be responsible for its
ability to increase the whole-body metabolic rate. The present study sought to determine the relative importance of white (subcutaneous AT
[sWAT] and visceral AT [vWAT]), and brown (interscapular brown AT [iBAT]) in governing FGF21-mediated metabolic improvements using the
tissue-speciﬁc uptake of glucose and lipids as a proxy for metabolic activity.
Methods: We used positron emission tomography-computed tomography (PET-CT) imaging in combination with both glucose (18F-ﬂuo-
rodeoxyglucose) and lipid (18F-4-thiapalmitate) tracers to assess the effect of FGF21 on the tissue-speciﬁc uptake of these metabolites and
compared responses to a control group pair-fed to match the food intake of the FGF21-treated group. In vivo imaging was combined with ex vivo
tissue-speciﬁc functional, biochemical, and molecular analyses of the nutrient uptake and signaling pathways.
Results: Consistent with previous ﬁndings, FGF21 reduced body weight via reduced caloric intake and increased energy expenditure in the
Siberian hamster. PET-CT studies demonstrated that FGF21 increased the uptake of glucose in BAT and WAT independently of reduced food
intake and body weight as demonstrated by imaging of the pair-fed group. Furthermore, FGF21 increased glucose uptake in the primary adi-
pocytes, conﬁrming that these in vivo effects may be due to a direct action of FGF21 at the level of the adipocytes. Mechanistically, the effects of
FGF21 are associated with activation of the ERK signaling pathway and upregulation of GLUT4 protein content in all fat depots. In response to
treatment with FGF21, we observed an increase in the markers of lipolysis and lipogenesis in both the subcutaneous and visceral WAT depots. In
contrast, FGF21 was only able to directly increase the uptake of lipid into BAT.
Conclusions: These data identify brown and white fat depots as primary peripheral sites of action of FGF21 in promoting glucose uptake and
also indicate that FGF21 selectively stimulates lipid uptake in brown fat, which may fuel thermogenesis.
 2019 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Fibroblast growth factor 21 (FGF21) is a member of the FGF super-
family that regulates metabolic homeostasis and is a potential thera-
peutic target for the treatment of metabolic syndrome [1].
Pharmacological administration of FGF21 to obese and diabetic animal
models results in multiple metabolic beneﬁts including improved
glucose homeostasis via increased insulin sensitivity and reduced body
weight [2e4]. FGF21’s pleiotropic effects are determined by the
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expression of KLB in adipose tissue (AT) and certain regions of the
brain dictate the tissue-speciﬁc actions of FGF21. Multiple studies
have implicated the importance of AT and the central nervous system
(CNS) for FGF21 biology. Deletion of the receptor isotype FGFR1 or KLB
from AT impairs the insulin-sensitizing effects of FGF21, and the ef-
fects of antibodies targeting FGFR1 are impaired in lipodystrophic mice
[7e10]. It was recently shown in mice genetically engineered to delete
KLB signaling from white AT (WAT) that AT is required for the acute
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food intake and energy expenditure in diet-induced obese rats, while
mice lacking KLB in the suprachiasmatic nucleus (SCN) and hindbrain
were refractory to the effects of FGF21 [12,13]. Furthermore, infusion
of FGF21 into the lateral ventricle in mice was shown to stimulate
browning of AT, which raises the possibility that some of the effects of
FGF21 on AT are centrally mediated [14].
We previously studied the biology of FGF21 action in the Siberian
hamster, a natural model of adiposity that increases body weight as it
accumulates AT in long day summer photoperiods (LD) but catabolizes
these depots to support winter survival in short photoperiods (SD) [15].
Hamsters in the LD state offer the possibility of studying the actions of
FGF21 in fat animals without the confounding effects of the develop-
ment of insulin resistance. We previously showed that FGF21 treat-
ment suppresses appetite and promotes lipid oxidation in the LD state,
but these effects are lost in the winter SD state, which is associated
with reduced adiposity [16]. Although the mechanisms underlying the
reduced responsiveness to FGF21 in the SD state are not yet known,
we also demonstrated that the effects of FGF21 are attenuated in aged
Siberian hamsters, which also display reduced adiposity [17], rein-
forcing the importance of AT in mediating the metabolic effects of
FGF21. In humans with type 2 diabetes (T2D), chronic administration of
FGF21 analogs lowers body weight and improves plasma lipid proﬁles
[18,19]. However, which speciﬁc adipose tissue depots may account
for the metabolic effects of FGF21 and the underlying mechanisms via
which these are achieved have yet to be fully elucidated [20].
In the present study, we sought to determine the relative importance of
different depots of AT (interscapular brown [iBAT], interscapular sub-
cutaneous white [sWAT], and peri-renal [visceral] white AT [vWAT]) in
governing FGF21-mediated metabolic improvements using a combi-
nation of in vivo studies utilizing quantitative PET-CT imaging with both
glucose and lipid tracers to assess the location and magnitude of their
uptake with ex vivo, metabolic, and molecular biology approaches. By
combining whole-body physiology along with mechanistic studies, we
demonstrate the adipose tissue-speciﬁc capacity for glucose and lipid
uptake and metabolism and the importance of adiposity, and in
particular KLB expression, in governing FGF21 responsiveness.
2. METHODS
2.1. Animals
Adult male Siberian hamsters were obtained from a colony maintained
at the University of Nottingham Biomedical Services Unit. All of the
studies were approved by the University of Nottingham Local Ethical
Review Committee and conducted in accordance with the UK Animals
(Scientiﬁc Procedures) Act of 1986 (project license: PPL 40/3604 and
PFBB5B31F). The Siberian hamsters were housed as previously
described [21]. Pair-fed (PF) hamsters were food restricted (twice
daily) to the average intake of FGF21-treated animals (offset by 48 h)
as previously described [22].
2.2. Chronic FGF21 (LY2405319) treatment
Prior to surgery, the animals were singly housed to accurately deter-
mine food intake. Age-matched animals in the LD (16 h light, 8 h dark)
and SD (16 h dark, 8 h light, lights off at 11:00) condition received a
subcutaneously implanted ALZET osmotic mini-pump (Model 1007D,
Charles River) releasing vehicle (saline) or FGF21 (LY2405319; 3 mg/
kg/day) for 7 days as previously described [17]. This infusion paradigm
was expected to increase the circulating FGF21 concentrations by at
least 2.5-fold over the course of the study. Food intake and body46 MOLECULAR METABOLISM 31 (2020) 45e54  2019 The Authors. Published by Elsevier Gweight were measured daily. Three days post-surgery, the animals
were transferred to metabolic cages (Columbus, Linton Instrumenta-
tion, UK).
2.3. Metabolic cages
Oxygen consumption and carbon dioxide production (used to calculate
the respiratory exchange ratio [RER] and energy expenditure [EE]) were
measured concurrently in a modiﬁed open-circuit calorimeter known
as the comprehensive laboratory animal monitoring system (CLAMS)
as previously described [21].
2.4. Assessment of body composition and whole-body glucose and
lipid uptake
Six days post-surgery, morphologic and molecular imaging was
undertaken using a nanopositron emission tomography-computed
tomography (nanoPET-CT) imaging scanner (Mediso Medical Imag-
ing Systems, Budapest, Hungary) to quantify the body composition,
and tissue-speciﬁc glucose and lipid uptake using 18F-ﬂuorodeox-
yglucose (18F-FDG) (10 MBq per animal) and 18F-4-thiapalmitate
(18F-PAL) (8 MBq per animal), respectively, as previously described
[23,24]. The magnitude of tissue-speciﬁc 18F-FDG and 18F-PAL
uptake was expressed as the standard uptake value (SUV) deﬁned as
the average 18F activity in each region of interest (in kBq/cm3) divided
by the injected dose (kBq) and multiplied by the body weight of each
animal (kg).
2.5. Primary adipocytes
All reagents were obtained from Sigma unless otherwise stated. Eight-
to 12-week-old male LD Siberian hamsters were used to obtain pri-
mary adipocytes. Brieﬂy, the fat pads (iBAT, sWAT, and vWAT) were
removed, chopped, and digested using collagenase D and dispase II at
37 C with constant agitation for 1 h in PBS containing 10 mM CaCl2.
The digestion was stopped by adding DMEM/F12, centrifuging at
900g for 10 min, and resuspension of the pellets in RBS Lysis Buffer
Solution, centrifuging at 900g for 10 min, and resuspension in
DMEM/F12 containing 10% FBS and pen/strep. The media were
changed every 2 days until 95% conﬂuent. To differentiate the BAT
cultures, the cells were treated with 5 mg/ml insulin, 1 nM T3, 125 mM
indomethacin, 2 mg/ml dexamethasone, 500 mM IBMX, and 0.5 mM
Rosi for 48 h. The WAT cultures were treated with 5 mg/ml insulin,
2 mg/ml dexamethasone, and 500 mM IBMX only for 48 h. On day 2,
the BAT cultures were treated with 5 mg/ml insulin, 1 nM T3, and
0.5 mM Rosi, while the WAT cultures were treated with 2 mg/ml
dexamethasone only. On days 4, 6, 8, and 10, the cells were main-
tained in DMEM/F12, 10% FBS, and pen/step before treatment with
100 nM LY2405319 for 48 h. Non-insulin stimulated glucose uptake
(normalized for protein content) was determined using [3H]2-
deoxyglucose as previously described [25].
2.6. Molecular and biochemical analysis
The animals were subsequently euthanized via an intraperitoneal in-
jection of sodium pentobarbital (Euthatal, Rhone Merireux, Harlow, UK).
Samples of the brain, liver, iBAT, sWAT, and vWAT were collected and
snap frozen on dry ice and stored at 80 C until required. Total RNA,
protein (see Supplementary Table 1 for antibody information and
Supplementary Fig. 4 for examples of Western blotting), and TAG were
extracted and analyzed as previously described [23,26]. Glycerol-3-
phosphate was determined according to the manufacturer’s in-
structions (Sigma MAK207, UK). Pyruvate dehydrogenase complex
(PDC) activity was determined as previously described [27].mbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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2.7. Statistical analysis
Descriptive statistics (means  SEM) were generated using GraphPad
Prism (Prism 7.0, GraphPad, San Diego, CA, USA). Data were analyzed
using two-way ANOVA, one-way ANOVA, or Student’s t-test as
appropriate. No animals were excluded from the analyses. Statistical
signiﬁcance was considered at p < 0.05.
3. RESULTS
3.1. Effects of FGF21 on body weight, activity, substrate oxidation
rates, and tissue thermogenic markers (Figure 1)
Chronic treatment with FGF21 signiﬁcantly reduced the body weight
and fat mass in the Siberian hamsters maintained in the LD fat state
(Figure 1B). Body weight loss was associated with a lowered daily
caloric intake and increased energy expenditure (Figure 1A,D). The
hamsters maintained in LD but pair-fed (PF) to match the intake of the
hamsters undergoing FGF21 treatment also lost body weight; however,
the magnitude of weight loss was attenuated when compared to the ab
libitum fed FGF21-treated animals (PF ¼ 12.8 vs FGF21 ¼ 18.1%,
p < 0.05, Figure 1B). Treatment with FGF21 reduced RER in the
hamsters maintained in LD, indicating an increase in whole-body lipid
oxidation (Figure 1C). This was a consequence of the FGF21 treatment
per se, as the PF animals maintained higher RER values that were
similar to the ab libitum fed vehicle control group (Figure 1C). Inter-
estingly, the PF animals also demonstrated increased EE; however, this
was limited to the dark phase (Figure 1D) and appeared to be a
consequence of increased ambulatory activity (Figure 1E). The
ambulatory activity of the FGF21-treated animals and vehicle-treated
controls was comparable (Figure 1E). The whole-body increase in
energy expenditure was associated with a signiﬁcant increase in UCP1
and DIO2 mRNA expression in iBAT, sWAT, and vWAT in the FGF21-
treated animals (Figure 1FeH). In the PF group, these thermogenic
markers were signiﬁcantly reduced compared to the vehicle-treated
control animals (Figure 1FeH).
3.2. Effects of FGF21 on tissue glucose uptake (Figure 1 and
Supplemental Fig. 1A)
We assessed tissue- and depot-speciﬁc glucose uptake in response to
treatment with FGF21 in vivo using nanoPET-CT and 18F-FDG. Treat-
ment with FGF21 increased the glucose uptake in iBAT, sWAT, and
vWAT compared to the vehicle-treated controls (Figure 1I,J). The in-
crease in the sWAT and vWAT depots was similar. This was a direct
effect of treatment, rather than a consequence of reduced food intake,
as glucose uptake in the PF group was similar to the ab libitum fed
control group (Figure 1I,J). Glucose uptake in response to treatment
was unaffected in the other tissues, including the brain, liver, muscle,
and testes (Supplemental Fig. 1A). To investigate whether the AT
response was a direct effect of the FGF21 treatment at the level of the
adipocyte, we treated the hamster primary adipocytes differentiated
from the stromal avascular cells isolated from iBAT, sWAT, and vWAT
with a pharmacological dose of FGF21 (100 nM for 48 h). FGF21
increased the glucose uptake signiﬁcantly in the cultures from both the
tissues and depots (Figure 1K). In line with the whole-tissue ﬁndings,
treatment with FGF21 also induced a 10- and 3-fold increase in UCP1
mRNA in the iBAT and WAT cultures, respectively (p < 0.01).
3.3. Effects of FGF21 on tissue-signaling proteins, transporters,
and enzymes (Figure 2, Supplemental Fig. 3)
Tissue-speciﬁc phosphorylation events downstream of the FGFR1c-
KLB receptor complex, namely pERK1/2, were signiﬁcantly increased
in the iBAT, sWAT, and vWAT of the FGF21-treated animalsMOLECULAR METABOLISM 31 (2020) 45e54  2019 The Authors. Published by Elsevier GmbH. This is a
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protein content (a downstream target of ERK1/2) in iBAT (Figure 2D).
This increase was not apparent in either WAT depot (Figure 2E,F).
However, GLUT4 protein (also a target of ERK1/2) was signiﬁcantly
increased in iBAT and both WAT depots (Figure 2GeI). There were no
changes in either GLUT1 or GLUT4 protein abundance in response to
PF in either tissue. ERK phosphorylation also contributes to AT lipolysis
[28,29]. In the present study, key markers of lipolytic capacity, namely
ATGL and pHSL660, were unaffected by treatment in iBAT
(Figure 2J,M); however, the PF group showed a signiﬁcant reduction in
both markers. In contrast, treatment with FGF21 increased the ATGL
content and pHSL660 in sWAT and vWAT (Figure 2K,L, 2N, and O,
respectively). These responses do not appear to be a consequence of
reduced food intake as there were no signiﬁcant changes in those
lipolytic proteins in the PF group compared to the control (saline) group.
The phosphorylation of ACC (pACC), a key enzyme in tissue lipogenesis
that controls the conversion of acetyl-CoA to malonyl-CoA, was un-
affected in iBAT by FGF21 treatment or reduced food intake in the PF
group (Figure 2P). However, pACC was reduced in WAT and therefore
its activity increased in response to FGF21 treatment (Figure 2QeR),
with a more pronounced effect observed in sWAT compared to vWAT.
We then assessed the activation of the PDC, which controls the con-
version of pyruvate to acetyl-CoA that is the substrate for ACC. Both the
FGF21-treated and PF animals demonstrated increases (0.49  0.10
and 0.33  0.07 nmol acetyl CoA/mg/min, p < 0.05, respectively) in
PDC activity in vWAT compared to the control (saline) group
(0.07  0.01 nmol acetyl CoA/mg/min). In BAT, there was a tendency
(p ¼ 0.09) for an increase in PDC activity in the FGF21
(1.48  0.45 nmol acetyl CoA/mg/min) but not PF group
(0.70  0.32 nmol acetyl CoA/mg/min) when compared with saline
(0.56  0.10 nmol acetyl CoA/mg/min).
3.4. Effects of FGF21 on tissue metabolites (Figure 3)
Treatment with FGF21 reduced the TAG content in iBAT and both WAT
depots (Figure 3A). Cold-activated BAT uses large amounts of TAG for
thermogenic purposes, and thus there is a biological need for efﬁcient
mechanism(s) ensuring the continuous replenishment of intracellular
lipid stores. This includes glucose uptake that is used for de novo
lipogenesis and glycerol synthesis [30]. This study measured the levels
of glycerol-3-phosphate (G3P), a key intermediate in lipogenesis that is
required for the re-esteriﬁcation of TAG. In line with increased glucose
uptake and ACC activity, treatment with FGF21 resulted in a signiﬁcant
increase in the G3P concentration in sWAT and vWAT, but not iBAT
(Figure 3B). In the PF control group, the levels of G3P were comparable
to the saline-treated animals.
3.5. Effects of FGF21 on tissue lipid uptake and associated
proteins (Figure 3 and Supplemental Fig. 1B)
Because both glucose and fatty acids are important substrates for the
replenishment of intracellular lipid stores in adipose tissue, we
sought to ascertain the impact of FGF21 on tissue-speciﬁc lipid
uptake in vivo. Utilizing nanoPET-CT and infusion of 18F-PAL, we
demonstrated that treatment with FGF21 signiﬁcantly increased lipid
uptake in BAT from the hamsters held in LD (Figure 3C). This was a
direct effect of treatment, rather than a consequence of reduced food
intake as demonstrated by the absence of lipid uptake in BAT in the
PF group. There was no effect of FGF21 treatment on WAT; however,
the PF group demonstrated reduced lipid uptake in that tissue.
Furthermore, lipid uptake in response to FGF21 treatment was un-
affected in the other tissues, including the brain, liver, quadriceps
muscle, and testes (Supplemental Fig. 1B). The selective increase inn open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 47
Figure 1: FGF21 reduces body weight via reduced food intake and increased energy expenditure in Siberian hamsters in long days (LD). (A) Food intake, (B) body weight,
(C) RER, (D) energy expenditure, (E) ambulatory activity, (F, G, and H) UCP1 and DIO2 mRNA expression in AT, and (I and J) glucose uptake of Siberian hamsters treated with FGF21,
vehicle, or pair-fed to match the food intake of the FGF21-treated group. Data are mean  SEM. N ¼ 4/group. *p < 0.05, ***p < 0.001. (K) Glucose uptake of primary adipocytes
derived from interscapular brown adipose (iBAT), interscapular subcutaneous white adipose (sWAT), or visceral (perirenal) white adipose (vWAT) treated with FGF21. N ¼ 8 per
treatment. Data presented as mean  SEM. *p < 0.05 vs vehicle control. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the Web version
of this article.)
Original Articlelipid uptake in BAT in response to FGF21 treatment was not asso-
ciated with altered mRNA expression of key proteins implicated in
lipid transport into that tissue, namely LPL, CD36, and FATP1
(Figure 3EeG) previously implicated in lipid disposal in BAT and WAT
[31]. However, there was an increase in the protein content of
PPARa, a transcriptional regulator of FGF21, in BAT in the PF group
compared with the control animals (Figure 3H).48 MOLECULAR METABOLISM 31 (2020) 45e54  2019 The Authors. Published by Elsevier G3.6. Importance of adiposity and KLB expression in governing
FGF21 responsiveness (Figure 4 and Supplemental Fig. 2)
Having described the distinct roles of different AT depots in medi-
ating the thermogenic and metabolic effects of FGF21 in the Siberian
hamsters maintained in the LD fat state, we next sought to deter-
mine the importance of the state of adiposity on these effects taking
advantage of our preclinical natural model of adiposity. We showedmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 2: FGF21-stimulated glucose uptake in adipose tissue relates to GLUT1 and GLUT4 protein expression in vivo. (AeC) pERK1/2 activation, (DeF) GLUT1 expression,
(GeI) GLUT4 expression, (JeL) ATGL expression, (MeO) pHSL660, and (PeR) pACC in iBAT, sWAT, and vWAT in response to treatment with FGF21 in vivo. Data are mean  SEM.
N ¼ 4/group. Statistical analyses conducted using one-way ANOVA with Tukey’s multiple comparison test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.transfer to SD for 12 weeks was associated with a reduction in
body weight. In line with our previous studies, the effects of treat-
ment with FGF21 were lost in this SD group at the nadir of their
body weight cycle: food intake, body weight, RER, energy expen-
diture, UCP1 and DIO2 gene expression in AT, and tissue
glucose uptake were all unaffected by FGF21 treatment
(Supplemental Fig. 2).MOLECULAR METABOLISM 31 (2020) 45e54  2019 The Authors. Published by Elsevier GmbH. This is a
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resistant state in the SD animals and the importance of tissue glucose
uptake in the increase in whole-body EE. We exposed a second group of
Siberian hamsters to SD for 8 weeks. At this point, their body weight was
signiﬁcantly reduced (Figure 4A) compared to that during LD, but the
animals were not at the nadir of the seasonal body weight cycle
observed after 12 weeks of exposure to SD. At this stage of the seasonaln open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 49
Figure 3: FGF21-stimulated lipid uptake in iBAT. (A) TAG and (B) G3P content of iBAT, sWAT, and vWAT and (C) lipid uptake in iBAT, sWAT, and vWAT in response to treatment
with FGF21 or vehicle or in pair-fed controls (PF). Data are mean  SEM. N ¼ 4/group. Statistical analyses conducted using one-way ANOVA with Tukey’s multiple comparison
test. *p < 0.05. (E) LPL, (F) CD36, (G) FATP1, and (H) PPARa expression in iBAT in response to treatment with FGF21 (vs saline controls). N ¼ 4/group. Data are mean  SEM.
N ¼ 4/group. Statistical analyses conducted using one-way ANOVA with Tukey’s multiple comparison test. *p < 0.05.
Original Articlecycle, treatment with FGF21 still signiﬁcantly reduced food intake and
body weight (Figure 4B,C). Furthermore, RER was signiﬁcantly reduced
(Figure 4D), indicating an increase in whole-body lipid oxidation. How-
ever, the effects of FGF21 on whole-body energy expenditure previously
observed in LD were lost (Figure 4E). As with the hamsters studied in LD,
there was no effect of FGF21 treatment on their ambulatory activity
(Figure 4F). In addition, UCP1 and DIO2 expression in BAT and WAT was
unaffected by treatment (Figure 4GeI). FGF21 treatment increased the
glucose uptake in sWAT and vWAT but not iBAT in this cohort (Figure 4J).
This suggests that the changes in glucose uptake in WAT were inde-
pendent of the changes in EE in this tissue, and instead the FGF21-
induced increase in EE in the LD animals was likely associated with
the increased thermogenesis in BAT. In the absence of treatment with
FGF21, the KLB levels in WAT in the hamsters exposed to SD for 8
weeks were comparable to the LD animals; while at the nadir of body
weight (12 weeks post-exposure to SD), KLB was signiﬁcantly reduced
in iBAT, sWAT, and vWAT (Figure 4K). KLB was also reduced in the PF
and FGF21 groups (Figure 4K); in the latter group, the weight loss was
similar to the SD group (PF ¼ 12.8%, FGF21 ¼ 18.1%,
SDþ 8¼9.8%, and SDþ 12 week group¼21.0%). This reduced
KLB in tissues in the SD þ 12 week group was associated with a
reduced pERK1/2 response to FGF21 (Figure 4L).50 MOLECULAR METABOLISM 31 (2020) 45e54  2019 The Authors. Published by Elsevier G4. DISCUSSION
This study provides novel insights into whole-body and adipose tissue-
speciﬁc depot mechanisms governing the metabolic effects of FGF21
in the Siberian hamster, a seasonal model of adiposity. The selective
increase in glucose uptake in the adipose tissue, which was a direct
consequence of FGF21 treatment rather than a result of the associated
changes in food intake, energy expenditure, and body weight,
appeared to be differentially regulated in WAT and BAT. In addition, we
demonstrated that lipid was exclusively taken up by BAT in response to
treatment with FGF21, possibly to fuel thermogenesis either directly by
being oxidized or indirectly by replenishing the TAG stores used for
thermogenesis. This lipid was most likely supplied by WAT, as the
markers of lipolysis in both sWAT and vWAT were upregulated in
response to FGF21 treatment. However, we also demonstrated
increased markers of TAG synthesis and de novo lipogenesis in both
WAT depots, but not BAT, as a result of treatment with FGF21. In the
absence of lipid uptake in WAT, our data suggest that the glucose
uptake in this tissue may be used to supply both fatty acyl CoAs
through the de novo lipogenesis pathway and the G3P required for the
re-esteriﬁcation of the glycerol backbone to TAG to provide further lipid
stores for subsequent utilization. In hamsters in LD, increased EEmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
www.molecularmetabolism.com
Figure 4: FGF21 reduces body weight via reduced food intake in Siberian hamsters in short days (SD) before body weight reaches a seasonal nadir. (A) Body weight
loss in response to exposure to SD. (B) Food intake, (C) body weight, (D) RER, (E) energy expenditure, (F) ambulatory activity, (GeI) UCP1 and DIO2 mRNA expression in AT, and (J)
glucose uptake in the Siberian hamsters treated with FGF21 or vehicle. Data are mean  SEM. N ¼ 4/group. Statistical analyses conducted using two-way ANOVA, one-way
ANOVA, or Students’ T-test as appropriate. *p < 0.05, ***p < 0.001, ****p < 0.0001. (K) KLB expression and (L) pERK1/2 in the Siberian hamsters in LD, treated with
FGF21, PF to treatment group, or exposed to SD (8 and 12 weeks, respectively). ap < 0.05 vs LD, bp < 0.05 vs SD þ 8 weeks or 12 weeks, respectively.
MOLECULAR METABOLISM 31 (2020) 45e54  2019 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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glucose uptake in BAT, but both effects were lost in SD. Finally, we
demonstrated that at the nadir of the bodyweight cycle, there was a
reduction in the expression of KLB associated with the loss of ERK1/2
phosphorylation in AT, altering its responsiveness to FGF21. Interest-
ingly, KLB was signiﬁcantly reduced in the PF group, suggesting that
weight loss per se altered the expression of this obligate co-receptor
for FGF21.
FGF21 was previously shown to be a potent regulator of glucose up-
take in 3T3-L1 adipocytes via GLUT1 [32]. Furthermore, FGF21 acts as
an insulin sensitizer in mice to overcome peripheral insulin resistance
induced by fasting in mice, an effect that is decreased in BAT of liver-
speciﬁc FGF21 KO mice [4]. The ﬁndings from the present study extend
those observations by combining mechanistic in vitro studies with an
in vivo model of seasonal adiposity using PET-CT measurements to
simultaneously assess in real time both the glucose and lipid uptake
responses to FGF21 treatment in multiple tissues and different depots
of AT. In the LD state, treatment with FGF21 signiﬁcantly increased the
glucose uptake in BAT and both depots of WAT, which was a direct
effect of treatment as demonstrated by the responses of the PF group
and data from the primary adipocyte cultures. The mechanism by
which glucose was taken up and its fate, however, were differentially
regulated. In BAT, we observed increases in GLUT1 and GLUT4 protein
content, suggesting insulin-independent and insulin-dependent
mechanisms, respectively. FGF21-induced GLUT1 expression in the
adipocytes was mediated by the Elk-1/SRF signaling cascade and was
blunted in the diet-induced obese mice [33]. In sWAT and vWAT, the
increase in glucose uptake was mediated by GLUT4 only. Over-
expression of FGF21 has been previously shown to increase GLUT4
mRNA expression in adipose tissue [34]. In the present study, we
extended that observation by showing an increase in the protein
content of GLUT4 in both the subcutaneous and visceral WAT depots as
well as BAT [35]. It should be noted that BAT depots in rodents and
humans are highly insulin sensitive. Indeed, insulin administration
enhances glucose uptake in BAT in response to FGF21 treatment [36].
In the present study, the magnitude of the effect of FG21 on the
glucose uptake in BAT was 2-fold higher than WAT, which may be
explained by the observation that GLUT4 is expressed at lower levels in
WAT and our data in the Siberian hamster supports this [37].
Furthermore, this may explain why humans, who possess relatively
less BAT, demonstrate less profound glucose lowering in response to
FGF21 treatment compared to rodents [18,19]. However, human BAT
has been shown to efﬁciently utilize fatty acids in vivo, and glucose
uptake in BAT is not impaired in overweight subjects with T2D [38,39].
Consistent with the FGF21-stimulated lipid uptake in BAT in the pre-
sent study, the blood lipid proﬁle is improved in humans treated with
FGF21 analogs [18,19]. Further clinical work is required to determine
the contribution of BAT in pre-clinical models and human subjects
(reviewed in [40]).
The increase in glucose uptake in WAT appears to contribute to the
regeneration of TAG. Indeed, treatment with FGF21 was shown to
activate ERK phosphorylation in that tissue and was associated with
increased content/activity of key markers of lipolysis (ATGL and pHSL),
de novo lipogenesis (ACC), and glycerol synthesis (G3P). The increase in
PDC activity in WAT, which controls the conversion of pyruvate to acetyl-
CoA, the substrate for ACC, further supports this notion. In contrast, the
absence of effects of FGF21 on pACC and G3P in BAT, along with the
tendency for an increase in PDC activity, suggests that most glucose
taken up is oxidized in that tissue and hence, unlike WAT, de novo
lipogenesis and glycerol synthesis do not substantially contribute to
replenishment of intracellular lipid stores under those conditions.52 MOLECULAR METABOLISM 31 (2020) 45e54  2019 The Authors. Published by Elsevier GWe also demonstrated that treatment with FGF21 increased lipid up-
take in BAT alone; we suggest the primary purpose of the lipid taken up
is to both replenish the intracellular TAG stores in this tissue and fuel
the increase in EE through thermogenesis. FGF21 may promote fatty
acid uptake in adipocytes directly or indirectly via insulin sensitization;
uptake was previously shown to be mediated via fatty acid transporters
such as CD36 or FATP1 in adipocytes [31,41]. Although the ﬁndings
from the present study indicate that the FGF21-induced uptake of lipid
in BAT was not mediated by upregulation in the protein content of
CD36, FATP1, or LPL, the possibility that changes in their intrinsic
activity may play a role cannot be ruled out. The selective utilization of
plasma-derived lipids in BAT, without further signiﬁcant storage in
WAT, may contribute not only to lipid lowering effects previously re-
ported but also to the weight loss and insulin sensitization effects of
FGF21 [31]. In addition, the increase in EE following treatment with
FGF21 in the LD animals was associated with an increase in glucose
and lipid uptake in BAT, although this effect was lost in the SD animals.
In contrast, the glucose uptake in WAT in response to treatment with
FGF21 was still evident in the SD state prior to body weight reaching a
nadir. This suggests that the FGF21-induced increase in glucose up-
take in WAT was independent of the whole-body changes in EE. This is
in contrast to previous suggestions that the increase in thermogenic
markers in WAT may stimulate glucose uptake via upregulation of
GLUT4 [35].
We previously highlighted the importance of adiposity per se in gov-
erning FGF21 responsiveness and demonstrated that Siberian ham-
sters at the nadir of their body weight cycle following exposure to SD
become completely unresponsive to exogenous FGF21 [16,17]. Here
we extend those ﬁndings and demonstrate that at the nadir of the body
weight cycle, KLB in all adipose tissue depots is reduced, and this is
associated with a loss of ERK1/2 phosphorylation in response to
treatment with FGF21. However, before body weight reaches a nadir,
the animals remain FGF21 responsive. As SD exposure enhances
sympathetic nervous system drive, increases UCP1 expression in BAT
and WAT, and induces lipolysis, FGF21 may be unable to further drive
this already maximal lipolytic and catabolic state at the nadir of the
body weight cycle [42,43].
Our data do not exclude a role for FGF21 in the CNS. Previously,
infusion of FGF21 into the lateral ventricle of mice was shown to
stimulate the browning of AT, an effect that was attenuated in mice
treated with a generic b-blocker and lost in mice lacking b-adrenor-
eceptors [14]. Further work is required to delineate the role of FGF21 in
the brain of the current seasonal model of adiposity. A role for hypo-
thalamic tanycytes in mediating the actions of FGF21 was recently
proposed [44]. Indeed, we previously demonstrated a role for FGFR1c
in tanycytes contributing to regulation of food intake, an effect probably
mediated by tanycytes regulating the local availability of thyroid hor-
mone in the surrounding hypothalamus [26]. In contrast to mice, which
demonstrate increased food intake in response to treatment with
FGF21, appetite in hamsters is consistently suppressed by FGF21
[3,16,17]. The FGF21-induced increase in appetite in mice is probably
a compensatory response to enhanced whole-body energy expendi-
ture, and therefore the defense of body weight or further metabolic fuel
to drive thermogenesis. A suppressive action of FGF21 on appetite in
hamsters is consistent with their known biology, in that a change in
ingestive behavior is a major driver of their seasonal cycle of adiposity.
Exposure of Siberian hamsters to SD for a period of weeks induces a
profound (w25%) chronic decrease in voluntary food intake, so
hypophagia is a natural state in this species. In addition, this natural
SD-induced hypophagia is associated with increased hepatic and
brown fat production of FGF21 [45]. Correspondingly, peripheralmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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treatment of Siberian hamsters with FGF21 results in upregulation of
Dio2 in the hypothalamus; this enzyme converts thyroid hormone into
its biologically active form [17]. Altered local concentration of thyroid
hormone is considered the main hypothalamic driver of the seasonal
cycle of appetite and energy expenditure in this species, and therefore
it is a likely central pathway of action for FGF21 [46,47].
5. CONCLUSIONS
Taken together, our studies reveal novel insights into the primary sites
and mechanisms of action of FGF21 using a preclinical natural model
of adiposity, the Siberian hamster. They also highlight the importance
of adipose tissue and KLB expression in governing the metabolic and
homeostatic actions of FGF21, which produce differential effects in
WAT and BAT, although we did not detect differences in the responses
of subcutaneous and visceral WAT to FGF21. Our data indicate that
glucose uptake in WAT may be used for de novo lipogenesis and TAG
synthesis, whereas the selective increase in lipid uptake in BAT may
fuel thermogenesis. These ﬁndings have important implications for
FGF21’s therapeutic potential in metabolic diseases that improve the
understanding of this hormone and how it can be further exploited in
future studies.
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